Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIONE phase 2 study of TD-1473 in Crohn's disease
MOH_2019-02-06_003644Phase 2Not yet recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of izencitinib in Crohn's disease (5 arms), sponsored by Theravance Biopharma, Inc. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
izencitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2019-02-06_003644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-06_003644.